Zenosense, Inc. (ZENO) Enters $475,000 Securities Purchase Agreement

Today, Zenosense, an emerging healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings for detection of the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug”, announced that it had entered into a securities purchase agreement with an accredited investor.

According to the agreement’s terms, Zenosense will engage in an initial sale of 55,556 shares of common stock at a gross sale price of $25,000. The accredited investor has agreed to the purchase of an additional 900,000 shares of common stock in four additional purchases, subject to certain conditions. The additional purchases will be commenced if Zenosense is successful in achieving its stage one development objective: the production of a prototype MRSA/SA sensor that is capable of detecting MRSA and/or SA contamination. When the objective has been met, the investor will make the first tranche purchase of 300,000 common stock shares for $150,000.

Once a month after the first tranche purchase has elapsed, the investor will make three additional consecutive monthly purchases of common stock. Each of these monthly purchases will comprise the purchase of 200,000 more shares of Zenosense’s common stock at a purchase price of $100,000. Zenosense will also be required to maintain a continuing listing of its common stock without interruption on at least one of the OTCQB, OTCQX, or equivalent replacement exchange such as the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange. Should Zenosense fail at any point to fulfill this listing requirement, the investor may terminate any balance due under the additional tranche purchases at the investor’s sole discretion.

To date, Zenosense has fully met its stage one obligation. Since December 2013, the healthcare technology company has provided over $520,000 in development funding to its partner, the Sgneia Group. Zenosense anticipates that 85 percent of the funding generated from the investor’s additional tranche purchases will be allocated toward stage two product development. That stage includes the producing and successfully conducting laboratory testing of 20 beta versions of the MRSA/SA sensor.

More information about Zenosense and its efforts in bringing-to-market innovations for healthcare-associated infections detection can be found at: www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net